News and Announcements
Natural Health Product Manufacturer with 22,000+ Terpene Products Sold | Selling to 120+ Outlets
- Published July 11, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Primal Organix is a natural health product manufacturer whose botanical terpene supplement drops interact with the human endocannabinoid system, enabling people to manage a range of health conditions and promote wellbeing.
Primal Organix addresses the most common chronic health conditions (e.g. mental health, respiratory, and sleep disorders) with an all-natural alternative solution to pharmaceutical drugs.
Primal Organix has generated A$792K in sales revenue having sold 22,000+ products to 120+ outlets (e.g. retail health food stores and pharmacies).
Investment Highlights
-
Primal Organix has generated A$792K in sales revenue and has sold 22,000+ products.
-
Product margin is more than 80% as a unit costs A$6.50 to manufacture and sells at a wholesale price of A$36.
-
Primal Organix sells to 120+ outlets (e.g. retail health food stores and pharmacies)
-
CEO Mark Garbelotto is an experienced business owner with a strong track record in sales. His first business generated millions of dollars in sales. Through his second business, the Australian Academy of Sales, he has trained over 10,000 people in increasing sales revenue.
-
Chief Science Officer Frank Giampieri has developed products to effectively manage his own disabling injury pain and has been working with doctors, specialists, and pharmacists to use his natural products to treat patients.
-
The global natural health supplements market is forecast to grow at an 8.0% CAGR to nearly A$100B by the end of 2024.
Investment Offering
Primal Organix is raising A$5M to expand its product range to include medical cannabis and nutraceutical hemp as well as to enter new global markets.
“The census shows that over eight million Australians have a long-term health condition. The WHO reports that mental health conditions are increasing worldwide, with depression and anxiety costing the global economy A$1T each year.
People want to overcome their health challenges with a safe, non-addictive, non-pharmaceutical solution. Terpene blended health products that work in conjunction with the endocannabinoid system will be the next wave in health and medicine.”
Mark Garbelotto
CEO
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
